Oral Antibody Therapy for Celiac Disease

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$145,306.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK080526-01A1
Agency Tracking Number:
R43DK080526
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA10-050
Small Business Information
AVAXIA BIOLOGICS, INC.
26 PEMBERTON RD, WAYLAND, MA, 01778-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
611725966
Principal Investigator:
BARBARA FOX
(508) 259-5929
bfox@avaxiabiologics.com
Business Contact:
ANNE BAIA
(781) 438-5755
annebaia@rcn.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Celiac disease is a common and debilitating gastrointestinal disorder. It is caused by an inappropriate immunological response to gluten. Although celiac disease can usually be controlled by strict avoidance of gluten in the diet, the ubiquity of gluten in the modern diet makes such a strategy difficult and there is a need for new therapies for celiac disease. This application tests the feasibility of using oral antibody therapy as an adjunctive therapy for celiac disease. Antibodies specific for gluten components may be able to block the immune response to gluten-derived peptides. Avaxia is developing AVX-176, a polyclonal anti-gluten antibody, that is designed to be ingested with meals to inhibit the response to low levels of gluten. AVX-176 is isolated from the colostrum (early milk) of cows that have been immunized with a component of gluten. Bovine colostral antibodies are stable to gastric digestion, safe for oral administration, and inexpensive to manufacture on a large scale. We have already produced the antibody to be used in this study. In this Phase I SBIR, the antibody will be tested for its ability to bind the proteins associated with toxicity in celiac disease: gliadin, glutenin, gluten-derived peptides, and related storage proteins from other grains. The ability of the antibody to inhibit activation of the innate immune system and enzyme-mediated peptide deamidation will also be assessed. These studies will establish the feasibility of using an orally delivered anti-gluten antibody for celiac disease. In the Phase II SBIR, the efficacy of the anti-gluten antibodies will be tested in in vivo models of celiac disease. In addition, the development and manufacture of GMP material suitable for a Phase I clinical trial will be initiated. It is hoped that these studies will lead to the rapid development of a new therapeutic agent for celiac disease. PUBLIC HEALTH RELEVANCE: Celiac disease is a common and debilitating gastrointestinal disorder that is caused by an inappropriate immune response to wheat gluten. This application is aimed at developing an oral antibody product that will bind to gluten and block its toxicity in the intestinal tract.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government